Cel Sci Corporation (CVM)

[Investors Hub Name]

Conditional approval in Canada and Europe for patients receiving Multikine + radiotherapy might be the best shot here. But that`s not going to happen in 2023. I guess rather second half of 2024. If they ever make it so far, the stock could do well. But they`ll need money pretty soon. Patients with advanced head and neck cancer represent an unmet medical need. The last FDA approval for advanced primary head and neck cancer is over 50 years ago. The current production capacity is estimated to be about 20,000 treatments annually. With a conservative estimate of 150.000,- USD per treatment (the annual cost of new cancer drugs in the USA jumped by 53% between 2017 and 2021, from $185 000 to more than $283 000) the company could generate 3 billion in sales a year. With the current float of shares (around 50M) that would be 60,- per share without any multiplier. The conditional marketing authorisation in Europe would only be for a year at the time.

Europe: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/conditional-marketing-authorisation

Canada: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380633/